

TEST CHANGE

Hereditary Cancer Panel, Sequencing and Deletion/Duplication 2012032, CANCERPAN

$\overline{}$		-	
Sn	acıman	Requirem	ante:
UΡ	CCIIIICII	ricquircii	CIICO.

Patient Preparation:

Collect: Lavender or pink (EDTA) or yellow (ACD solution A or B).

Specimen Preparation: Transport 3 mL whole blood. (Min: 2 mL)

Transport Temperature: Refrigerated

Unacceptable Conditions: Serum or plasma; grossly hemolyzed or frozen specimens;

saliva, buccal brush, or swab; FFPE tissue; DNA.

Remarks:

Stability: Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable

New York State Clients: Preferred Ambient: 4 days; Refrigerated: 4 days; Frozen: 4 days It is preferred that specimens be received within 4 days of collection. Extraction will be attempted for specimens received after 4 days, and DNA yield will be evaluated to determine if testing may proceed.

Effective Date: October 6, 2025

Methodology: Massively Parallel Sequencing // Sequencing // Multiplex

Ligation-Dependent Probe Amplification (MLPA)

Performed: Varies

Reported: 14-21 days

Note: Genes Tested: ALK; APC*; ATM; AXIN2; BAP1; BARD1;

BMPR1A*; BRCA1*; BRCA2; BRIP1; CDC73; CDH1*; CDK4; CDKN1B; CDKN2A*; CHEK2*; CTNNA1*; DICER1; EGFR; EPCAM**; FH; FLCN*; HOXB13; HRAS; KIT; LZTR1; MAX; MC1R; MEN1*; MET; MITF*; MLH1; MLH3*; MSH2; MSH3; MSH6; MUTYH; NBN; NF1; NF2; NTHL1; PALB2; PDGFRA*; PMS2; POLD1; POLE; POT1; PRKAR1A; PTCH1; PTEN*;

RAD51C; RAD51D; RB1*; RECQL*; RET; SDHA*; SDHAF2; SDHB; SDHC*; SDHD*; SMAD4; SMARCA4; SMARCB1; SMARCE1*; STK11; SUFU; TERT; TMEM127; TP53; TSC1; TSC2; VHL*; WT1 *- One or more exons are not covered by sequencing and/or deletion/duplication analysis for the indicated gene; see Additional Technical Information. **- Deletion/duplication analysis of EPCAM (NM_002354) exon 9 only, sequencing is

not available for this gene.

AR	\mathbf{P}°
LARODATO	DIES

CPT Codes: 81162; 81201; 81292; 81295; 81298; 81307; 81317; 81321;

81351; 81403; 81404; 81405; 81406; 81407; 81408; 81479

Effective Date: October 6, 2025

New York DOH Approval Status: Specimens from New York clients will be sent out to a New

York DOH approved laboratory, if possible.

Interpretive Data:

Refer to report. Refer to report

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Reference Interval:

By report